AILERON THERAPEUTICS, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 19th, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations • New York
Contract Type FiledJune 19th, 2017 Company Industry Jurisdiction
INDEMNIFICATION AGREEMENTIndemnification Agreement • June 19th, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations • Delaware
Contract Type FiledJune 19th, 2017 Company Industry JurisdictionThis Indemnification Agreement (“Agreement”) is made as of [•], 2017 by and between Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), and [•] (the “Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.
AILERON THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • June 19th, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations • Massachusetts
Contract Type FiledJune 19th, 2017 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between Aileron Therapeutics, Inc., a Delaware corporation (the “Company”) and Donald Dougherty of Boston, MA (the “Executive”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • June 19th, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations • Massachusetts
Contract Type FiledJune 19th, 2017 Company Industry JurisdictionThis Amended and Restated License Agreement (this “Agreement”) is entered into as of the 19th day of February, 2010 (the “Effective Date”), for the purpose of amending and replacing the License Agreement dated August 2, 2006 (the “Original Agreement”), by and among: Aileron Therapeutics, Inc. (formerly Renegade Therapeutics, Inc.), a Delaware corporation, having a principal place of business at 840 Memorial Drive, 2nd Floor, Cambridge, MA 02142 (“Licensee”); President and Fellows of Harvard College, Holyoke Center, Suite 727, 1350 Massachusetts Ave., Cambridge, MA (“Harvard”); and Dana-Farber Cancer Institute, Inc., 44 Binney Street, Boston, MA (“DFCI”). Harvard and DFCI shall be referred to together as “Licensors”.
AILERON THERAPEUTICS, INC. NONSTATUTORY STOCK OPTION AGREEMENTNonstatutory Stock Option Agreement • June 19th, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations
Contract Type FiledJune 19th, 2017 Company IndustryThis option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
AILERON THERAPEUTICS, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • June 19th, 2017 • Aileron Therapeutics Inc • Pharmaceutical preparations
Contract Type FiledJune 19th, 2017 Company IndustryThis option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.